Intensity Therapeutics Reports Q3 2025 Financial Results with Reduced Net Loss

Intensity Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $2.7 million, a decrease from a net loss of $3.5 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $8.6 million, down from $13.1 million in the prior year. The reduction in losses is attributed to a significant decrease in operating expenses, which totaled $2.7 million for the quarter, compared to $3.6 million in Q3 2024, and $8.8 million for the nine-month period, down from $13.4 million in the previous year.

The company’s cash and cash equivalents increased to $7.1 million as of September 30, 2025, up from $2.6 million at the end of 2024. This increase was primarily driven by financing activities, which generated $11.3 million in cash during the nine months ended September 30, 2025, largely from public offerings and an At The Market (ATM) sales agreement. The company has issued a total of 23 million shares under the ATM agreement, raising approximately $7.7 million since its inception. However, the company has not yet generated any revenue from product sales, as it remains focused on the development of its lead drug candidate, INT230-6.

Operationally, Intensity Therapeutics has paused new patient enrollments in its Phase 3 INVINCIBLE-3 Study due to funding constraints, although it continues to treat enrolled patients. The company also paused new patient enrollment in the Phase 2 INVINCIBLE-4 Study to revise the dosing regimen after observing localized skin irritation in some patients. These pauses reflect the company's ongoing challenges in securing sufficient funding to support its clinical trials.

The company’s research and development expenses decreased significantly, with a 28% reduction in Q3 2025 compared to the same quarter in 2024, primarily due to lower costs associated with the INVINCIBLE-3 Study. General and administrative expenses also fell by 17% in the same period, reflecting cost-saving measures and reduced business development activities. Despite these reductions, the company anticipates continued significant expenses as it advances its clinical programs and seeks regulatory approvals.

Looking ahead, Intensity Therapeutics expects to incur substantial losses as it continues to fund its clinical studies and operational needs. The company has indicated that it will rely on equity offerings and convertible debt to finance its operations, as it does not expect to generate significant revenue in the near term. The company believes it has sufficient cash to support its operations until the end of the first quarter of 2027, but it acknowledges the ongoing need for additional funding to sustain its development efforts.